Thermo Cardiosystems
This article was originally published in The Gray Sheet
Executive Summary
Abiomed withdraws offer to acquire firm after Thermo's board of directors reaffirms its commitment to proceed with its planned merger with Thoratec Labs (1"The Gray Sheet" Jan. 22, 2001, In Brief)
You may also be interested in...
Thermo Cardiosystems
Board of directors reaffirms its commitment to proceed with its planned merger with Thoratec Laboratories following a revised, unsolicited, rival bid from Abiomed Jan. 18. Since Abiomed launched the eleventh-hour counter-bid Jan. 4, the firm has increased the percentage of its $11.50-per-share offer that it is willing to pay in cash. The most recent proposal would allow some Thermo Cardiosytems shareholders to elect to receive all cash or all stock, although the aggregate amount of cash and stock distributed would remain the same as in the previous offer (1"The Gray Sheet" Jan. 15, 2001, p. 3). Thermo Cardiosystems shareholders will vote on the Thoratec merger Feb. 13. Separately, Thoratec announced it has filed an investigational device exemption application with FDA for trials of an implantable version of its ventricular assist device (IVAD) for patients awaiting a heart transplant or recovery from open heart surgery
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.